Top-News

ATHERONOVA INC News

Keine aktuellen Kursdaten verfügbar
WKN: A1C1AE
ISIN: US0474383041
US-Symbol: AHROQ
Typ: Aktie

ATHERONOVA INC News

30.07.14 - PR Newswire
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 Anticipate Topline Data in 6-8 months PR Newswire
05.12.13 - PR Newswire
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis PR Newswire
15.10.13 - PR Newswire
Atherosclerosis Researcher Dr. Erik Stroes Joins AtheroNova's Clinical Advisory Board
Atherosclerosis Researcher Dr. Erik Stroes Joins AtheroNova's Clinical Advisory Board PR Newswire
27.06.13 - PR Newswire
AtheroNova Announces Publication of Positive Pre-Clinical Results with AHRO-001 in the FASEB Journal
AtheroNova Announces Publication of Positive Pre-​Clinical Results with AHRO-001 in the FASEB Journal Preclinical Study Conducted by David Geffen School of Medicine at UCLA ...
25.06.13 - PR Newswire
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis PR Newswire
30.05.13 - PR Newswire
AtheroNova Announces Shipment of Phase 1 Drug Product
AtheroNova Announces Shipment of Phase 1 Drug Product Phase 1 Commencement in June PR Newswire
17.04.13 - PR Newswire
Noted Atherosclerosis Researcher Joins AtheroNova Team
Noted Atherosclerosis Researcher Joins AtheroNova Team Dr. John Kastelein Appointed Co-​Principal Investigator PR Newswire
15.04.13 - PR Newswire
/C O R R E C T I O N -- AtheroNova Inc./
/C O R R E C T I O N -- AtheroNova Inc./ PR Newswire
15.04.13 - PR Newswire
AtheroNova Adds New Medical Advisor
AtheroNova Adds New Medical Advisor Dr. John Kastelein Appointed Co-​Principal Investigator PR Newswire
11.04.13 - PR Newswire
AtheroNova Adds New Medical Advisor
AtheroNova Adds New Medical Advisor Dr. Stephen Nicholls named as Chair of Clinical Advisory Board PR Newswire
14.03.13 - PR Newswire
AtheroNova Announces Shareholder Realignment
AtheroNova Announces Shareholder Realignment PR Newswire
17.01.13 - PR Newswire
AtheroNova to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference
AtheroNova to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference PR Newswire
08.01.13 - PR Newswire
AtheroNova Names New Clinical Affairs Officer
AtheroNova Names New Clinical Affairs Officer Joan Shaw Named to Clinical Post PR Newswire
18.12.12 - PR Newswire
AtheroNova Names New Chief Medical Officer
AtheroNova Names New Chief Medical Officer Dr. Mark Wedel Named to Senior Post PR Newswire
18.12.12 - PR Newswire
AtheroNova Names New Chief Medical Officer
AtheroNova Names New Chief Medical Officer Dr. Mark Wedel Named to Senior Post PR Newswire
15.11.12 - PR Newswire
AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383 Dissolution of Arterial Plaque Using Hyodeoxycholic Acid PR Newswire
13.11.12 - PR Newswire
AtheroNova Announces Milestone Filing of IND in Russian Federation
AtheroNova Announces Milestone Filing of IND in Russian Federation Licensing Partner formally applies to the Ministry of Healthcare PR Newswire
07.11.12 - PR Newswire
AtheroNova Names New Director
AtheroNova Names New Director Fred Knoll of Knoll Capital Management Joins the Board of Directors PR Newswire
11.10.12 - PR Newswire
AtheroNova Completes $2.9 Million Private Placement of Common Stock
AtheroNova Completes $2.9 Million Private Placement of Common Stock Provides Runway Through Phase I & II Clinical Trials PR Newswire
09.10.12 - PR Newswire
Additional Study to Commence at The David Geffen School of Medicine at the University of California Los Angeles (UCLA)
Additional Study to Commence at The David Geffen School of Medicine at the University of California Los Angeles (UCLA) PR Newswire

Newssuche

Videos

newspaper
30.04.24 -9,41%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »